

STAMPEDE Abiraterone Chartered Criteria (De-novo patients)	ADT Alone		ADT + AAP		Adjusted HR (95% CI)	Interaction between metastatic subgroups p-value
	No. of events/ No. of patients					
Overall Survival						
Overall	192/431	130/428			0.59 (0.47-0.74)	
Low	52/182	36/191			0.60 (0.39-0.92)	
High	140/249	94/237			0.59 (0.45-0.76)	0.85
Failure Free Survival						
Overall	343/431	182/428			0.30 (0.25-0.37)	
Low	127/182	52/191			0.24 (0.18-0.34)	
High	216/249	130/237			0.32 (0.25-0.40)	0.40
Skeletal Related Events						
Overall	159/431	90/428			0.47 (0.36-0.60)	
Low	43/182	24/191			0.47 (0.29-0.78)	
High	116/249	66/237			0.46 (0.34-0.62)	0.84
Progression Free Survival						
Overall	258/431	150/428			0.44 (0.36-0.53)	
Low	81/182	41/191			0.39 (0.27-0.57)	
High	177/249	109/237			0.44 (0.35-0.56)	0.70
Prostate Cancer Specific Death						
Overall	170/431	109/428			0.57 (0.44-0.72)	
Low	43/182	28/191			0.57 (0.35-0.94)	
High	127/249	81/237			0.57 (0.43-0.75)	0.92

0 0.1 0.2 0.3 0.4 0.5 0.6 0.7 0.8 0.9 1 1.1 1.2

Favours ADT + AAP



Favours ADT